Drugs / Methoxyverapamil
Methoxyverapamil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00896428 | Dec 2009 → Jul 2012 | asthma | University Hospital, Bordeaux | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methoxyverapamil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00896428 ↗ |
| Known as | D-600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL523367 ↗ |
| Known as | DL-D-600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL523367 ↗ |
| Known as | gallopamil | “Methoxyverapamil (gallopamil)” NCT00896428 ↗ |
| Known as | LU-30-029 | ChEMBL registry synonym — accepted as the source's own label CHEMBL523367 ↗ |
| Action | Inhibit | “In vitro, the Ca(2+)-channel blocker gallopamil decreased the proliferation of BSM cells from patients with severe asthma.” PMID 25633090 ↗ Apr 2015 |
| Modality | Small molecule | — CHEMBL523367 ↗ |